Dedicated to "Making Mad Bank

Mallinckrodt strongly believes that our commitment to the patient drives our search for higher prices. Far too often patients are unable to take advantage of programs that provide free prescription medications because their personal income or assets are too high. By raising the prices of Mallinckrodt drugs, we can remove the income or assets that have prevented these patients from qualifying for free prescriptions medications. The humanitarian nature of our approach to price has been recognized by the public as Mark True Dough has been awarded a trophy for humanitarian of the year.

After paying $100 million to settle charges that it quashed competition for its blockbuster med H.P. Acthar Gel, Mallinckrodt is facing more legal heat. In a lawsuit (PDF) filed late Monday, plaintiffs representing Medicare Advantage Organizations accuse the company of blocking competition and dramatically raising prices on its lead med.

The plaintiffs say Mallinckrodt and Questcor have raised H.P. Acthar Gel prices 85,000% since 2001. Mallinckrodt purchased Questcor in 2014 and inherited some of the legal issues tied to the drug, including a Federal Trade Commission probe.

To stifle competition, the plaintiffs argue, Questcor's U.S. unit purchased the rights to a potential competitor from Novartis in 2011, then sidelined that med and continued raising prices on Acthar. After Mallinckrodt bought Questor, price hikes and anticompetitive behavior continued, the lawsuit claims.

Mallinckrodt strongly believes that none of the company actions outlined in the plaintiff’s complaint constitute a violation of any law and, therefore, believes that the complaint should be dismissed in its entirety. We will vigorously defend the company in this matter. Raising prices is our right, and we plan to be mighty right.